Avadel Pharmaceuticals (AVDL) Non-Current Debt (2016 - 2022)
Historic Non-Current Debt for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $109.9 million.
- Avadel Pharmaceuticals' Non-Current Debt fell 2262.85% to $109.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $109.9 million, marking a year-over-year decrease of 2262.85%. This contributed to the annual value of $142.4 million for FY2021, which is 1106.54% up from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Non-Current Debt is $109.9 million, which was down 2262.85% from $108.1 million recorded in Q2 2022.
- Avadel Pharmaceuticals' Non-Current Debt's 5-year high stood at $142.4 million during Q4 2021, with a 5-year trough of $1.9 million in Q2 2020.
- In the last 5 years, Avadel Pharmaceuticals' Non-Current Debt had a median value of $115.7 million in 2018 and averaged $93.0 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Non-Current Debt plummeted by 8802.48% in 2020, and later surged by 730721.0% in 2021.
- Avadel Pharmaceuticals' Non-Current Debt (Quarter) stood at $115.7 million in 2018, then increased by 5.14% to $121.7 million in 2019, then increased by 5.36% to $128.2 million in 2020, then grew by 11.07% to $142.4 million in 2021, then fell by 22.8% to $109.9 million in 2022.
- Its Non-Current Debt was $109.9 million in Q3 2022, compared to $108.1 million in Q2 2022 and $116.5 million in Q1 2022.